Buradasınız

Anasayfa » Content

VELAGLUCERASE ALFA: AN ENZYME REPLACEMENT THERAPY IN GAUCHERS DISEASE

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2012

Key Words:

Author Name
Abstract (2. Language): 
Gaucher's disease is an inherited metabolic disease that is presented as a multi-system disease. Enzyme replacement aims to reduce the accumulated waste material within these macrophages by augmenting the activity of the enzyme and attempting to restore the cell back to normality. This study increasing focuses on patient satisfaction and preservation of quality of life in patients with Gaucher's Disease who receiving their enzyme replacement therapy with Velaglucerase alfa.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-velaglucerase-alfa-enzyme-replacement-therapy-gauchers-disease.pdf
  • 2
  • English

REFERENCES

References: 

1.
Meikl
e PJ, Hopwood JJ, Clague AE and Carey WF: Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-54.
2.
Biegstraate
n M, van Schaik IN, Aerts JM and Hollak CE: Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 2008; 31: 337-49.
3. Beutler
E
, Nguyen NJ, Henneberger MW, Smolec JM, McPherson RA and West C: Gaucher disease: Gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993; 52: 85-88.
4. Beutler E and Grabowski GA: Glucosylceramide lipidosis-Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular bases of inherited diseases. 8th Ed. New York: McGraw-Hill (2001). pp. 3635-68.
5.
Feroz
e M, Arvindan KP and Jose L Gaucher's disease among Mappila muslims of Malabar. Indian J Pathol Microbiol 1994;
37: 307-11.
6.
Gauche
r PC: De l'epithelioma primitive de la rate, hypertrophie idiopathique de la rate sans leukemia. Paris: MD Thesis 1882.
7.
Epstei
n E: Beitrag zurchemie der Gaucherschen krankeit. Biochem Z 1924; 145: 398-402.
8.
Brad
y RO, Kanfer JN and Shapiro D: Metabolism of glucocerebrosides.II: Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965; 18: 221-5.
9. Schnabel
D
, Schroder M and Sandhoff K. Mutation in the sphingolipid activator protein 2 in a patient with a variant of gaucher disease. FEBS Lett 1991; 284: 57¬9.
10.
Corman
d B, Montfort M, Chabas A, Vilageliu L and Grinberg D: Genetic fine localization of the beta-glucocerebrosidase (GBA) and prosaposin (PSAP) genes: Implications for Gaucher disease. Hum Genet 1997; 100: 75-9.
11. Zimran A, Elstein D. Lipid storage diseases. In: Lichtman MA, Kipps T, Seligsohn U, Kaushansky K, Prchal JT, ed.
Williams Hematology. 8th ed; New York,
NY: McGraw-Hill (2010):1065-1071.
12.
Barto
n NW, Brady RO and Dambrosia JM: Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324:1464-1470.
13.
Co
x T, Lachmann R and Hollak C: Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet. 2000; 355:1481-1485.
14. Sorge J, West C, Westwood B and Beutler E: Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc Natl Acad Sci U S A 1985; 82:
7289-7293.
15.
Horowit
z M, Wilder S, Horowitz Z, Reiner O, Gelbart T and Beutler E: The human glucocerebrosidase gene and pseudo gene: structure and evolution. Genomics. 1989; 4(1): 87-96.
16. Brady RO: Enzyme replacement therapy for lysosomal diseases. Annu. Rev. Med
2006; 57: 283-296.
17. Zimran A: Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995; 345, 1479-1480.
18. Cox TM: Management of non-neuronopathic gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J. Inherit. Metab. Dis 2008; 31: 319-336.
19. Brumshtein, B: Characterization of gene-activated human acid-b-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2009; 20: 24-32.
20. US Food and Drug Administration (FDA). FDA labeling information — Vpriv (velaglucerase Alfa). FDA website [online],
(2010).
21. European Medicines Agency (EMA). European Public Assessment Report —
Vpriv. EMA website [online], (2010).
22. Zimran A: Phase 1/2 and extension study of velaglucerase Alfa replacement therapy in adults with type 1 gaucher disease: 48-month experience. Blood 115, 4651-4656
(2010).
23. Pastores GM: Therapeutic goals in the treatment of gaucher disease. Semin. Hematol 2004; 41: 4-14.
24. Zimran A, Altarescu G, Phillips M, Attias D, Jmoudiak M, Deeb M, Wang N,
Bhirangi K, Cohn GM and Elstein D: Phase I/II and extension study of velaglucerase Alfa (Gene-Activated TM human glucocerebrosidase) replacement therapy in adults with type 1 gaucher disease: 48-month experience. Blood 2010.
25.
VPriv
™ (velaglucerase Alfa) for injection [product information]. Cambridge, MA: Shire Human Genetic the era pies Inc, Feb 2010.
26.
Fong CT. Lysosomal storage disorders. In Merck Manuals Online Medical Library. Available from: http://www.merck.com/mmpe/print/sec19/ch 296/ch296f.html (Accessed January 25,
2011)
27.
Brumshtei
n B, Salinas P, Peterson B, Chan V, Silman I, Sussman JL, Savickas PJ, Robinson GS and Futerman AH: Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010; 20: 24¬32.

Thank you for copying data from http://www.arastirmax.com